GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sansure Biotech Inc (SHSE:688289) » Definitions » Total Assets

Sansure Biotech (SHSE:688289) Total Assets : ¥8,571 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sansure Biotech Total Assets?

Sansure Biotech's Total Assets for the quarter that ended in Sep. 2024 was ¥8,571 Mil.

During the past 12 months, Sansure Biotech's average Total Assets Growth Rate was 14.50% per year. During the past 3 years, the average Total Assets Growth Rate was 42.50% per year. During the past 5 years, the average Total Assets Growth Rate was 64.50% per year.

During the past 7 years, Sansure Biotech's highest 3-Year average Total Assets Growth Rate was 94.50%. The lowest was 34.10%. And the median was 60.40%.

Total Assets is connected with ROA %. Sansure Biotech's annualized ROA % for the quarter that ended in Sep. 2024 was 1.80%. Total Assets is also linked to Revenue through Asset Turnover. Sansure Biotech's Asset Turnover for the quarter that ended in Sep. 2024 was 0.04.


Sansure Biotech Total Assets Historical Data

The historical data trend for Sansure Biotech's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sansure Biotech Total Assets Chart

Sansure Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial 642.47 5,459.93 7,090.37 9,173.76 8,454.21

Sansure Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,307.76 8,454.21 8,745.54 8,632.08 8,571.19

Sansure Biotech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Sansure Biotech's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=7424.907+1029.298
=8,454

Sansure Biotech's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=7353.067+1218.127
=8,571

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sansure Biotech  (SHSE:688289) Total Assets Explanation

Total Assets is connected with ROA %.

Sansure Biotech's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=154.884/( (8632.08+8571.194)/ 2 )
=154.884/8601.637
=1.80 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Sansure Biotech's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=315.623/( (8632.08+8571.194)/ 2 )
=315.623/8601.637
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Sansure Biotech Total Assets Related Terms

Thank you for viewing the detailed overview of Sansure Biotech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sansure Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205
Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.
Executives
Tan De Yong Core technical personnel
Wang Hai Xiao senior management
Jie Ya Ping Core technical personnel
Zhang Ke Ya Core technical personnel
Yang Li Core technical personnel
Liu Rang Jiao Core technical personnel
Deng Zhong Ping Senior management, core technical personnel
Zhou Jun senior management
Zhu Jian senior management
Wu Kang Core technical personnel
Xiong Xiao Yan senior management
Ji Bo Zhi Core technical personnel
Mou Wei Min Core technical personnel
Ren Xiao Mei Core technical personnel
Liu Kai senior management

Sansure Biotech Headlines

No Headlines